ArticleRNA (New York, N.Y.)2019
Structural insights into nanoRNA degradation by human Rexo2.
Article in RNA (New York, N.Y.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 17 citations in OpenAlex.
- Pathway-based cancer transcriptome deciphers a high-resolution intrinsic heterogeneity within bladder cancer classification.Journal of translational medicine · 2025Article
- A temperature-driven DNA discrimination strategy to distinguish E. coli DNA and phage 5hmC-modified DNA.Nucleic acids research · 2025Article
- Heterozygous de novo dominant negative mutation of REXO2 results in interferonopathy.Nature communications · 2024Article
- Nano-RNases: oligo- or dinucleases?FEMS microbiology reviews · 2022Review
- How RNases Shape Mitochondrial Transcriptomes.International journal of molecular sciences · 2022Review
- Crystal structure of oligoribonuclease from Vibrio cholerae O1 El Tor with bound peptide.Acta crystallographica. Section F, Structural biology communications · 2021Article
- Article
- Human Mitochondrial RNA Processing and Modifications: Overview.International journal of molecular sciences · 2021Review
- Human REXO2 controls short mitochondrial RNAs generated by mtRNA processing and decay machinery to prevent accumulation of double-stranded RNA.Nucleic acids research · 2020Article
- Germline variant inGenetics research · 2020Article
- A novel 5'-hydroxyl dinucleotide hydrolase activity for the DXO/Rai1 family of enzymes.Nucleic acids research · 2020Article
- Dinucleotide Degradation by REXO2 Maintains Promoter Specificity in Mammalian Mitochondria.Molecular cell · 2019Article
- A dedicated diribonucleotidase resolves a key bottleneck for the terminal step of RNA degradation.eLife · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human RNA exoribonuclease 2 (Rexo2) is an evolutionarily conserved 3'-to-5' DEDDh-family exonuclease located primarily in mitochondria. Rexo2 degrades small RNA oligonucleotides of <5 nucleotides (nanoRNA) in a way similar to
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.